CBS - The 17th Left Main & Coronary Bifurcation Summit, CBS2025

HOME
CBS 2019
At CBS

General Information

Left Main & Coronary Bifurcation Summit (CBS) was founded in 2006 as a think tank dedicated to the treatment of left main and coronary bifurcation lesions. CBS aims to improve cardiological care by refreshing fundamental researches, clinical trials, yearly published guidelines, emerged ideas and case-based discussion.

Association and Affiliations
- Organized by
  
  Nanjing Heart Center
  
  Asian Bifurcation Club (ABC)
  
  Nanjing First Hospital, Nanjing Medical University
- Co-organized by
  
  Chinese Society of Cardiology (CSC)
  
  Capacity Building and Continuing Education Center,National Health and Family Planning Commission (CBCEC)
  
  American Society for Cardiovascular Angiography and Interventions (SCAI)
  
  Asian Heart Society (AHS)
Contact Us
- Registration Administration of Domestic Representatives
  
  Hongjuan Peng : +86-13913895477
  
  Haimei Xu +86-13914736846
  
  cbsnj@cbsmd.cn
- Registration Administration of Overseas Representatives
  
  Ling Lin : +86 (25) 52271398
  
  +86-13951884596
  
  cbs@cbsmd.cn
- Management of Challenging Cases
  
  Yingying Zhao :+86-13815408517
  
  sub@cbsmd.cn
Address

CBS2019 Congress Secretariat, Nanjing First Hospital, Building No.9 68# Changle Road, Nanjing, China

210006
FACULTY
FACULTY

General Chairman
Congress Chairman
Course Directors International Faculty Domestic Faculty Hong Kong and Taiwan Faculty Members of Academic Committee
Education Center

Education Center

• Online Education (For more customized user interface with self-defined collection of research papers and education resources.)

• CBS Education Resource

• CBSMD Scientific Library
SCIENTIFIC LIBRARY

SCIENTIFIC LIBRARY

Research Paper

> Acute Coronary Syndrom

> ASCVD Prevention

> Bifurcation Stenting

> Cardio-Oncology

> Congestive Heart Failure

> DAPT Duration

> Drug Coated Balloon

> Fractional Flow Reserve

> IVUS Guidance

> Optical Coherence Tomography

> Pulmonary Hypertension

> Rotational Atherectomy

> Shear Stress

> Stenting Left Main

> Transcatheter Aortic Valve Replacement

> Percutaneous LAA Occlusion

> Mitral/Tricuspid Valvular Disease

> Other Relevant Articles

Recommended Paper

Management of Acute Myocardial Infarction During the COVID-19 Pandemic

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19)

HOME | SCIENTIFIC LIBRARY | DAPT Duration

DAPT Duration

P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Dual antiplatelet therapy: how, how long, and in which patients? A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent

Sort by hits |<<... 6 7 8 9 10 11 12 ...>>|

JOURNAL：CBS2017 Article Link

Make a Voice to the World

CBS2017

Denver - October 29, from 11 to 11:30 a.m., Dr Peter Block gave Prof Shao-Liang Chen from Nanjing First Hospital an in-depth interview in the Colorado Convention Center at TCT2017 (Transcatheter Cardiovascular Therapy conference). Prof Shao-Liang Chen is the initiator of DK Crush-V, which using randomized, prospective, multinational design to evaluate the efficacy and safety of DK crush over provisional side branch stenting for patients with unprotected left main bifurcation lesions.

With the further development of interventional devices , coronary bifurcation lesions remains as the one of the most challenging cardiovascular diseases to be tackled. Varies of treatment strategies need high reliability, high level of evidence before promoted in global clinical practices. With passion and faith for better clinical outcome, Prof Chen and his research team keep working on this issue over ten years, seeking a better treatment strategy for unprotected left main bifurcation lesions. This time, he share his professional clinical experiences and perspectives with international colleagues about the "Current practice and perspectives on treatment in left main bifurcation in China" at TCT2017.

As the leading event in the fields of left main coronary artery disease and transcatheter valve disease, this year, TCT2017 presents 12 LBCTs and 16 FRIs to cause attention. The progress of DK-V is one of the most notable results, which will be released on October 30th at 11:40 am, local time (at 1:40 a.m. on November 1, Beijing time).

Important Events at TCT2017

Abstract

Recommended Article

Make a Voice to the World